



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 21-May-2024

Revision Number 1.2

60024PE 60024PE.1 - Anti-Rat CD90 Antibody, Clone OX-7, PE


Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Document Number DX22038

Product Name Anti-Rat CD90 Antibody, Clone OX-7, PE

Pure substance/mixture Mixture

DocuSigned by:

 1A130E8E320B4AF...
 2024-05-22

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Laboratory reagent

Uses advised against No information available

1.3. Details of the supplier of the safety data sheet

Manufacturer

STEMCELL Technologies SARL
 40 Rue des Berges, Miniparc Polytec, Bâtiment Sirocco, 38000 Grenoble, France
 +33 (0) 4 76 04 75 30
 STEMCELL Technologies Germany GmbH
 Stolberger Str. 200, 50933, Köln, Germany
 +33 (0) 4 76 04 75 30
 STEMCELL Technologies UK Ltd.
 Building 7100, Cambridge Research Park, Beach Drive, Waterbeach, Cambridge, UK, CB25 9TL
 +33 (0) 4 76 04 75 30

For further information, please contact

1.4. Emergency telephone number

Emergency Telephone No information available

Emergency Telephone - §45 - (EC)1272/2008

Europe 112

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Regulation (EC) No 1272/2008

This mixture is classified as not hazardous according to regulation (EC) 1272/2008 [CLP]

2.2. Label elements

This mixture is classified as not hazardous according to regulation (EC) 1272/2008 [CLP]



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

60024PE 60024PE.1 - Anti-Rat CD90 Antibody, Clone OX-7, PE

Revision Date 21-May-2024

Revision Number 1.2

Hazard statements

This mixture is classified as not hazardous according to regulation (EC) 1272/2008 [CLP]

2.3. Other hazards

No information available

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Synonym

Not applicable

3.2 Mixtures

The product contains no substances which at their given concentration, are considered to be hazardous to health

This mixture is classified as not hazardous according to regulation (EC) 1272/2008 [CLP]

Full text of H- and EUH-phrases: see section 16

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Wash skin with soap and water. In the case of skin irritation or allergic reactions see a physician.
Ingestion	Clean mouth with water and drink afterwards plenty of water.

4.2. Most important symptoms and effects, both acute and delayed

Symptoms No information available.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians Treat symptomatically.



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

60024PE 60024PE.1 - Anti-Rat CD90 Antibody, Clone OX-7, PE

Revision Date 21-May-2024

Revision Number 1.2

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable Extinguishing Media No information available.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical No information available.

5.3. Advice for firefighters

Special protective equipment for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Ensure adequate ventilation.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions See Section 12 for additional Ecological Information.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Take up mechanically, placing in appropriate containers for disposal.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

60024PE 60024PE.1 - Anti-Rat CD90 Antibody, Clone OX-7, PE

Revision Date 21-May-2024

Revision Number 1.2

7.1. Precautions for safe handling

Advice on safe handling Ensure adequate ventilation.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities Store in accordance with information listed on the Product Information Sheet (PIS).

7.3. Specific end use(s)

Identified Uses

Risk Management Methods (RMM) The information required is contained in this Material Safety Data Sheet.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies.

Derived No Effect Level (DNEL) No information available.

Predicted No Effect Concentration (PNEC) No information available.

8.2. Exposure controls

Personal protective equipment

Eye/face protection No special protective equipment required.

Skin and body protection No special protective equipment required.

Respiratory protection No protective equipment is needed under normal use conditions. If exposure limits are exceeded or irritation is experienced, ventilation and evacuation may be required.



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 21-May-2024

Revision Number 1.2

60024PE 60024PE.1 - Anti-Rat CD90 Antibody, Clone OX-7, PE

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

Environmental exposure controls No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Liquid
Appearance	Clear
Color	No information available
Odor	No data available.
Odor threshold	No data available

Property	Values	Remarks • Method
pH	No data available	None known
Melting point / freezing point	No data available	None known
Boiling point / boiling range	No data available	None known
Flash point	No data available	None known
Evaporation rate	No data available	None known
Flammability (solid, gas)	No data available	None known
Flammability Limit in Air		None known
Upper flammability limit:	No data available	
Lower flammability limit:	No data available	
Vapor pressure	No data available	None known
Vapor density	No data available	None known
Relative density	No data available	None known
Water solubility	No data available	None known
Solubility(ies)	No data available	None known
Partition coefficient	No data available	None known
Autoignition temperature	No data available	None known
Decomposition temperature	No data available	None known
Kinematic viscosity	No data available	None known
Dynamic viscosity	No data available	None known
Explosive properties	No information available	
Oxidizing properties	No information available	

9.2. Other information

Softening point	No information available
Molecular weight	No information available
Molecular formula	No information available
VOC Content (%)	No information available
Liquid Density	No information available
Bulk density	No information available

Section 10: STABILITY AND REACTIVITY



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 21-May-2024

Revision Number 1.2

60024PE 60024PE.1 - Anti-Rat CD90 Antibody, Clone OX-7, PE

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under recommended transport or storage conditions.

Explosion data

Sensitivity to Mechanical Impact None.

Sensitivity to Static Discharge None.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions None under normal processing.

10.4. Conditions to avoid

Conditions to avoid None known based on information supplied.

10.5. Incompatible materials

Incompatible materials None known based on information supplied.

10.6. Hazardous decomposition products

Hazardous decomposition products None known based on information supplied.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on toxicological effects

Information on likely routes of exposure

Product Information

Inhalation Specific test data for the substance or mixture is not available.

Eye contact Specific test data for the substance or mixture is not available.

Skin contact Specific test data for the substance or mixture is not available.

Ingestion Specific test data for the substance or mixture is not available.

Symptoms related to the physical, chemical and toxicological characteristics



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 21-May-2024

Revision Number 1.2

60024PE 60024PE.1 - Anti-Rat CD90 Antibody, Clone OX-7, PE

Symptoms No information available.

Numerical measures of toxicity

Acute toxicity

The following values are calculated based on chapter 3.1 of the GHS document

Unknown acute toxicity 0 % of the mixture consists of ingredient(s) of unknown toxicity.
 0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity.
 100 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity.
 100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas).
 100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor).
 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).

Product Information

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation No information available.

Product Information

Serious eye damage/eye irritation No information available.

Product Information

Respiratory or skin sensitization No information available.

Product Information

Germ cell mutagenicity No information available.

Product Information

Carcinogenicity No information available.

Product Information

Reproductive toxicity No information available.

Product Information

STOT - single exposure No information available.

Product Information

STOT - repeated exposure No information available.

Product Information

Aspiration hazard No information available.



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

60024PE 60024PE.1 - Anti-Rat CD90 Antibody, Clone OX-7, PE

Revision Date 21-May-2024

Revision Number 1.2

Section 12: ECOLOGICAL INFORMATION

12.1. Toxicity

Ecotoxicity

Unknown aquatic toxicity Contains 0 % of components with unknown hazards to the aquatic environment.

Product Information

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

12.6. Other adverse effects

Other adverse effects No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation.

Contaminated packaging Do not reuse empty containers.

Section 14: TRANSPORT INFORMATION



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 21-May-2024

Revision Number 1.2

60024PE 60024PE.1 - Anti-Rat CD90 Antibody, Clone OX-7, PE

IMDG

14.1 UN Number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing Group	Not regulated
14.5 Marine pollutant	Not applicable
14.6 Special Provisions	None
14.7. Transport in bulk according to Annex II of MARPOL and the IBC Code	No information available

RID

14.1 UN Number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing Group	Not regulated
14.5 Environmental hazard	Not applicable
14.6 Special Provisions	None

ADR

14.1 UN Number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing Group	Not regulated
14.5 Environmental hazard	Not applicable
14.6 Special Provisions	None

IATA

14.1 UN Number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing Group	Not regulated
14.5 Environmental hazard	Not applicable
14.6 Special Provisions	None

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 21-May-2024

Revision Number 1.2

60024PE 60024PE.1 - Anti-Rat CD90 Antibody, Clone OX-7, PE

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009 Not applicable

International Inventories

TSCA	Complies
DSL/NDL	Complies
EINECS/ELINCS	Complies
ENCS	Does not comply
IECSC	Complies
KECL	Complies
PICCS	Complies
AICS	Complies

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
KECL - Korean Existing and Evaluated Chemical Substances
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Legend

SVHC: Substances of Very High Concern for Authorization:

Legend Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

TWA	TWA (time-weighted average)	STEL	STEL (Short Term Exposure Limit)
Ceiling	Maximum limit value	*	Skin designation



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

60024PE 60024PE.1 - Anti-Rat CD90 Antibody, Clone OX-7, PE

Revision Date 21-May-2024

Revision Number 1.2

Revision Date 21-May-2024

This material safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006

Disclaimer


The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product.

Certificate Of Completion

Envelope Id: EF6BB66905AB4631AF50C2D020CB1BA9	Status: Completed
Subject: Complete with DocuSign: DX22038-SDS_1_2_0_EU.pdf	
Source Envelope:	
Document Pages: 11	Signatures: 1
Certificate Pages: 5	Initials: 0
AutoNav: Enabled	Envelope Originator:
Envelopeld Stamping: Enabled	Cory Thomson
Time Zone: (UTC-08:00) Pacific Time (US & Canada)	1618 Station Street
	Suite 500
	Vancouver, BC V6A 1B6
	cory.thomson@stemcell.com
	IP Address: 50.92.193.176

Record Tracking

Status: Original	Holder: Cory Thomson	Location: DocuSign
2024-05-22 05:28	cory.thomson@stemcell.com	

Signer Events	Signature	Timestamp
Ruth Gill ruth.gill@stemcell.com Program Lead, Official Documentation Security Level: Email, Account Authentication (None)	DocuSigned by:  1A130E8E320B4AF... Signature Adoption: Pre-selected Style Using IP Address: 50.68.18.181	Sent: 2024-05-22 05:29 Viewed: 2024-05-22 08:42 Signed: 2024-05-22 08:42

Electronic Record and Signature Disclosure:
Accepted: 2023-10-06 | 11:37
ID: 67ca97d0-c1e4-4718-a39b-0e991cdebbac

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp

Carbon Copy Events	Status	Timestamp
Sharon McAuliffe sharon.mcauliffe@stemcell.com Security Level: Email, Account Authentication (None)	COPIED	Sent: 2024-05-22 08:42 Viewed: 2024-05-22 12:29
Electronic Record and Signature Disclosure: Accepted: 2024-05-15 15:41 ID: d2968336-dfa0-4def-b5e9-dc24f64b097a		
QAS Document Control qasdocumentcontrol@stemcell.com Security Level: Email, Account Authentication (None)	COPIED	Sent: 2024-05-22 08:42 Viewed: 2024-05-22 10:26
Electronic Record and Signature Disclosure: Not Offered via DocuSign		

Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2024-05-22 05:29
Certified Delivered	Security Checked	2024-05-22 08:42
Signing Complete	Security Checked	2024-05-22 08:42
Completed	Security Checked	2024-05-22 08:42
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Stemcell Technologies Inc (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Stemcell Technologies Inc:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: mark.schuetz@stemcell.com

To advise Stemcell Technologies Inc of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at mark.schuetz@stemcell.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Stemcell Technologies Inc

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to mark.schuetz@stemcell.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Stemcell Technologies Inc

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to mark.schuetz@stemcell.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Stemcell Technologies Inc as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Stemcell Technologies Inc during the course of your relationship with Stemcell Technologies Inc.